Publications
2023
Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe
Taieb, J., Seufferlein, T., Reni, M., Palmer, D. H., Bridgewater, J. A., Cubillo, A., . . . Macarulla, T. (2023). Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe. BMC CANCER, 23(1). doi:10.1186/s12885-023-11377-1
Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways
Quinn, L. M., Haldenby, S., Antzcak, P., Fowler, A., Bullock, K., Kenny, J., . . . Goldring, C. (n.d.). Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways. Scientific Reports, 13(1). doi:10.1038/s41598-023-33096-0
PINCER (A Platform Study for solId orgaN CancERs): an agile pan-network platform study to deliver high-quality translational research
Jones, R. P., Mielgo, A., Schmid, M., Bury, D., Andrews, T., Burdak-Rothkamm, S., . . . Vimalachandran, D. (2023). PINCER (A Platform Study for solId orgaN CancERs): an agile pan-network platform study to deliver high-quality translational research. BRITISH JOURNAL OF SURGERY. doi:10.1093/bjs/znad097
The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100P Gene Expression in Cells and in an In Vivo Model of Pancreatic Cancer
Ahmed, A. A., Greenhalf, W., Palmer, D. H., Williams, N., Worthington, J., Arshad, T., . . . Neidle, S. (2023). The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100P Gene Expression in Cells and in an In Vivo Model of Pancreatic Cancer. MOLECULES, 28(6). doi:10.3390/molecules28062452
GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma
de Andres, M. P., Jackson, R. J., Felipe, I., Zagorac, S., Pilarsky, C., Schlitter, A. M., . . . Real, F. X. (2023). GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. GUT, 72(3), 535-548. doi:10.1136/gutjnl-2021-325803
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
Kudo, M., Finn, R. S., Qin, S., Han, K. -H., Ikeda, K., Cheng, A. -L., . . . Lencioni, R. (2023). Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.. Journal of hepatology, 78(1), 133-141. doi:10.1016/j.jhep.2022.09.006
Ultrasonography in surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
Hydes, T. J., Cuthbertson, D. J., Palmer, D. H., Elshaarawy, O., Johnson, P. J., Fernando, R., & Cross, T. J. (2023). Ultrasonography in surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. HEPATOMA RESEARCH, 9. doi:10.20517/2394-5079.2022.97
2022
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
Ghaneh, P., Palmer, D., Cicconi, S., Jackson, R., Halloran, C. M., Rawcliffe, C., . . . European Study Group for Pancreatic Cancer. (2022). Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.. The lancet. Gastroenterology & hepatology, S2468-1253(22)00348-X. doi:10.1016/s2468-1253(22)00348-x